Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | Director · See remarks | July 28, 2026 | July 30, 2026 |
| SomaLogic, Inc.CMII · Entity 95310 | Director | February 22, 2021 | February 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 74,258 |
Reported balance
After 2026-07-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 74,258 · Balance 74,258 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 309,467 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 309,467 · Balance 309,467 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.
F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.
SomaLogic, Inc.
Report date February 22, 2021 · Filed February 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252626) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252626) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2022 Filed Dec 1, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 102,676 | $1.79 | $184,098.07 |
DisclosureSEC source: 0000899243-22-037295 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,119,168 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 96,433 | $1.90 | $183,126.27 |
DisclosureSEC source: 0000899243-22-037295 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,221,844 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 99,798 | $1.99 | $198,997.21 |
DisclosureSEC source: 0000899243-22-037048 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,318,277 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 22, 2022 Filed Nov 25, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 101,813 | $2.04 | $208,003.96 |
DisclosureSEC source: 0000899243-22-037048 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,418,075 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 103,765 | $2.10 | $217,906.50 |
DisclosureSEC source: 0000899243-22-036788 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,519,888 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 98,562 | $2.17 | $213,879.54 |
DisclosureSEC source: 0000899243-22-036788 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,623,653 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 17, 2022 Filed Nov 19, 2022 02:00 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 221,402 | $2.09 | $461,623.17 |
DisclosureSEC source: 0000899243-22-036457 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,722,215 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 16, 2022 Filed Nov 19, 2022 02:00 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 219,089 | $2.43 | $531,290.83 |
DisclosureSEC source: 0000899243-22-036457 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,943,617 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 212,443 | $2.51 | $533,231.93 |
DisclosureSEC source: 0000899243-22-036024 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,162,706 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 208,633 | $2.72 | $567,064.49 |
DisclosureSEC source: 0000899243-22-036024 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,375,149 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 02:00 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 197,964 | $2.65 | $525,396.46 |
DisclosureSEC source: 0000899243-22-035784 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,583,782 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:00 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 186,028 | $2.46 | $457,628.88 |
DisclosureSEC source: 0000899243-22-035784 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,781,746 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 207,960 | $2.43 | $505,550.76 |
DisclosureSEC source: 0000899243-22-035553 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,967,774 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 193,616 | $2.46 | $475,520.90 |
DisclosureSEC source: 0000899243-22-035553 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,175,734 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 205,809 | $2.42 | $497,440.35 |
DisclosureSEC source: 0000899243-22-035376 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,369,350 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 22:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 204,906 | $2.51 | $513,494.44 |
DisclosureSEC source: 0000899243-22-035376 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,575,159 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 196,308 | $2.77 | $543,380.54 |
DisclosureSEC source: 0000899243-22-034953 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,780,065 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 197,899 | $2.71 | $535,316.80 |
DisclosureSEC source: 0000899243-22-034707 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,976,373 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 199,307 | $2.63 | $523,380.18 |
DisclosureSEC source: 0000899243-22-034707 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,174,272 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 22:50 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 204,478 | $2.71 | $553,317.47 |
DisclosureSEC source: 0000899243-22-034478 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,373,579 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 26, 2022 Filed Oct 28, 2022 22:50 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 189,138 | $2.90 | $549,256.75 |
DisclosureSEC source: 0000899243-22-034478 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,578,057 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 25, 2022 Filed Oct 26, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 187,442 | $2.64 | $495,596.65 |
DisclosureSEC source: 0000899243-22-034281 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,767,195 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 206,504 | $2.48 | $511,510.41 |
DisclosureSEC source: 0000899243-22-034281 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,954,637 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 201,371 | $2.44 | $491,546.61 |
DisclosureSEC source: 0000899243-22-034035 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,161,141 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 196,721 | $2.47 | $485,507.43 |
DisclosureSEC source: 0000899243-22-034035 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,362,512 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 211,829 | $2.50 | $529,360.67 |
DisclosureSEC source: 0000899243-22-033896 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,559,233 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 198,051 | $2.64 | $523,448.79 |
DisclosureSEC source: 0000899243-22-033896 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,771,062 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 195,317 | $2.64 | $515,441.56 |
DisclosureSEC source: 0000899243-22-033760 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,969,113 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 215,948 | $2.62 | $565,135.92 |
DisclosureSEC source: 0000899243-22-033760 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,164,430 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 207,271 | $2.74 | $567,093.46 |
DisclosureSEC source: 0000899243-22-033673 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,380,378 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 211,066 | $2.81 | $593,095.46 |
DisclosureSEC source: 0000899243-22-033673 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,587,649 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 11, 2022 Filed Oct 12, 2022 23:58 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 200,435 | $2.87 | $575,048.02 |
DisclosureSEC source: 0000899243-22-033509 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,798,715 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 23:58 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 213,575 | $2.88 | $614,882.43 |
DisclosureSEC source: 0000899243-22-033509 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,999,150 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 343,082 | $3.12 | $1,070,964.77 |
DisclosureSEC source: 0000899243-22-032861 · doc4.xml · nonDerivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,212,725 F4 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032861 · doc4.xml · derivative · entry 6 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032861 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,555,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 773,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032861 · doc4.xml · derivative · entry 4 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,929,596 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 773,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032861 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 01:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GiftClass A Common Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047408 · doc4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions being reported herein relate to a charitable donation of shares of Class A Common Stock. The donated shares remain subject to transfer restrictions in accordance with the Issuer's certificate of incorporation. Read SEC document |
| December 06, 2021 Filed Dec 9, 2021 01:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | ConversionClass B Common Stock · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-047408 · doc4.xml · derivative · entry 3 Kelly Jason R · CIK 0001845677 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,703,049 Underlying: Class A Common Stock · 150,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · price: Pursuant to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. ("Legacy Ginkgo"), as contemplated by an agreement and plan of merger, dated May 11, 2021 and amended on May 14, 2021 (the "Merger Agreement"), (a) each share of Class A common stock of Legacy Ginkgo outstanding immediately prior to the effective time of the business combination was converted into approximately 49.080452 shares of the Issuer's Class A Common Stock; and (b) each share of Class B common stock of Legacy Ginkgo outstanding immediately prior to the effective time of the business combination was converted into approximately 49.080452 shares of the Issuer's Class B Common Stock. F4 · price: Pursuant to the Merger Agreement, each share of Class A common stock of Legacy Ginkgo, each share of Class B common stock of Legacy Ginkgo, each option of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, each award of restricted common stock of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, and each award of restricted stock units of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, in each case outstanding immediately prior to the effective time of the business combination, received a proportional amount of the approximately 188.7 million earn-out shares. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| December 06, 2021 Filed Dec 9, 2021 01:07 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | ConversionClass A Common Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-047408 · doc4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions being reported herein relate to a charitable donation of shares of Class A Common Stock. The donated shares remain subject to transfer restrictions in accordance with the Issuer's certificate of incorporation. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| November 17, 2021 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032861 · doc4.xml · derivative · entry 5 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,782,354 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person. Read SEC document |
| September 16, 2021 Filed Sep 21, 2021 01:43 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass B Common Stock · Derivative | 11,728,057 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036671 · doc4.xml · derivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · CEO & Founder 10b5-1 filing: Not disclosed Ownership: Indirect · By GRAT Disclosed balance after: 11,728,057 Underlying: Class A Common Stock · 11,728,057 shares Expires not disclosed F1 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A common stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · price: Pursuant to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. ("Legacy Ginkgo"), as contemplated by an agreement and plan of merger, dated May 11, 2021 and amended on May 14, 2021 (the "Merger Agreement"), (a) each share of Class A common stock of Legacy Ginkgo outstanding immediately prior to the effective time of the business combination was converted into approximately 49.080452 shares of the Issuer's Class A Common Stock; and (b) each share of Class B common stock of Legacy Ginkgo outstanding immediately prior to the effective time of the business combination was converted into approximately 49.080452 shares of the Issuer's Class B Common Stock. F3 · price: Pursuant to the Merger Agreement, each share of Class A common stock of Legacy Ginkgo, each share of Class B common stock of Legacy Ginkgo, each option of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, each award of restricted common stock of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, and each award of restricted stock units of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, in each case outstanding immediately prior to the effective time of the business combination, received a proportional amount of the approximately 188.7 million earn-out shares. F1 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A common stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A common stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes 1,256,546 earn-out shares that will vest in four substantially equal installments if the Issuer's Class A common stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $12.50, $15.00, $17.50 and $20.00. Read SEC document |
| September 16, 2021 Filed Sep 21, 2021 01:43 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantClass B Common Stock · Derivative | 70,853,049 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036671 · doc4.xml · derivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · CEO & Founder 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,853,049 Underlying: Class A Common Stock · 70,853,049 shares Expires not disclosed F1 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A common stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · price: Pursuant to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. ("Legacy Ginkgo"), as contemplated by an agreement and plan of merger, dated May 11, 2021 and amended on May 14, 2021 (the "Merger Agreement"), (a) each share of Class A common stock of Legacy Ginkgo outstanding immediately prior to the effective time of the business combination was converted into approximately 49.080452 shares of the Issuer's Class A Common Stock; and (b) each share of Class B common stock of Legacy Ginkgo outstanding immediately prior to the effective time of the business combination was converted into approximately 49.080452 shares of the Issuer's Class B Common Stock. F3 · price: Pursuant to the Merger Agreement, each share of Class A common stock of Legacy Ginkgo, each share of Class B common stock of Legacy Ginkgo, each option of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, each award of restricted common stock of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, and each award of restricted stock units of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, in each case outstanding immediately prior to the effective time of the business combination, received a proportional amount of the approximately 188.7 million earn-out shares. F1 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A common stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A common stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F4 · balance_after: Includes 10,353,539 earn-out shares that will vest in four substantially equal installments if the Issuer's Class A common stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $12.50, $15.00, $17.50 and $20.00. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.